AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a ...

I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.

AbbVie (NYSE:ABBV) just scored a big win for its next-generation arthritis drug. The company said Monday that Rinvoq ...

The Food & Drug Administration granted AbbVie expanded approval for its Rinvoq drug intended to treat moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease ...

ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.

(Reuters) -AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller ...

The FDA has approved AbbVie’s supplemental new drug application for Rinvoq (upadacitinib) to treat inflammatory bowel disease ...

AbbVie (ABBV) on Monday said that the U.S. Food and Drug Administration has approved an update to the indication statement ...

The Food and Drug Administration (FDA) has approved updated indications for Rinvoq® (upadacitinib) in the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn ...

In Q3, the top 10 TV ad spenders poured a combined $544.8 million into airing their commercials, according to data shared ...

AbbVie has received the U.S. Food and Drug Administration (FDA) approval for a supplemental new drug application (sNDA) that ...

The updated indication for the JAK inhibitor allows use in patients with moderately to severely active ulcerative colitis and ...